Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment

Ciara McCabe, Zevic Mishor, Philip J Cowen, Catherine J Harmer, Ciara McCabe, Zevic Mishor, Philip J Cowen, Catherine J Harmer

Abstract

Background: Selective serotonin reuptake inhibitors (SSRIs) are popular medications for anxiety and depression, but their effectiveness, particularly in patients with prominent symptoms of loss of motivation and pleasure, has been questioned. There are few studies of the effect of SSRIs on neural reward mechanisms in humans.

Methods: We studied 45 healthy participants who were randomly allocated to receive the SSRI citalopram, the noradrenaline reuptake inhibitor reboxetine, or placebo for 7 days in a double-blind, parallel group design. We used functional magnetic resonance imaging to measure the neural response to rewarding (sight and/or flavor of chocolate) and aversive stimuli (sight of moldy strawberries and/or an unpleasant strawberry taste) on the final day of drug treatment.

Results: Citalopram reduced activation to the chocolate stimuli in the ventral striatum and the ventral medial/orbitofrontal cortex. In contrast, reboxetine did not suppress ventral striatal activity and in fact increased neural responses within medial orbitofrontal cortex to reward. Citalopram also decreased neural responses to the aversive stimuli conditions in key "punishment" areas such as the lateral orbitofrontal cortex. Reboxetine produced a similar, although weaker effect.

Conclusions: Our findings are the first to show that treatment with SSRIs can diminish the neural processing of both rewarding and aversive stimuli. The ability of SSRIs to decrease neural responses to reward might underlie the questioned efficacy of SSRIs in depressive conditions characterized by decreased motivation and anhedonia and could also account for the experience of emotional blunting described by some patients during SSRI treatment.

Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
(A) Sight of chocolate condition (placebo [Plac] > citalopram [Cital]). Axial, sagittal, and coronal image of increased ventral striatal activation in the placebo group compared with the citalopram group ([6 14 −8], z = 3.79, p < .001, family-wise error corrected). Paramenter estimates from 6-mm sphere centered at 14 6 −8 for citalopram, reboxetine (Rebox), and placebo.
Figure 2
Figure 2
(A) Chocolate in the mouth with the sight of chocolate (reboxetine [Rebox] > placebo [Plac]): axial, sagittal, and coronal image of increased medial orbitofrontal cortex/frontal pole activation in the reboxetine group compared with the placebo ([10 42 −30], z = 3.01, p = .05 false discovery rate small volume corrected). (B) Parameter estimates from 6-mm sphere centered at 10 42 −30 for citalopram (Cital), reboxetine, and placebo.
Figure 3
Figure 3
(A) Sight of moldy strawberries condition (placebo [Plac] > citalopram [Cital]): axial, sagittal, and coronal image of increased lateral orbitofrontal cortex activation in the placebo group compared with the citalopram group ([32 26 −4], z = 5.12, p = .002, family-wise error corrected). (B) Parameter estimates from 6-mm sphere centered at 32 26 −4 for citalopram, reboxetine (Rebox), and placebo.
Figure 4
Figure 4
(A) Strawberry in the mouth with the sight of moldy strawberries (placebo [Plac] > citalopram [Cital]): axial, sagittal, and coronal image of increased lateral orbitofrontal cortex activation in the placebo group compared with the citalopram group ([30 26 2], z = 4.22, p < .001, family-wise error corrected). (B) Parameter estimates from 6-mm sphere centered at 30 26 2 for citalopram, reboxetine, and placebo.

References

    1. Bauer M., Monz B.U., Montejo A.L., Quail D., Dantchev N., Demyttenaere K. Prescribing patterns of antidepressants in Europe: Results from the factors influencing depression endpoints research (FINDER) study. Eur Psychiatry. 2008;23:66–73.
    1. Fergusson D., Doucette S., Glass K.C., Shapiro S., Healy D., Hebert P. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. BMJ. 2005;330:396.
    1. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–260.
    1. Watson D., O'Hara M.W., Stuart S. Hierarchical structures of affect and psychopathology and their implications for the classification of emotional disorders. Depress Anxiety. 2008;25:282–288.
    1. Shelton R.C., Tomarken A.J. Can recovery from depression be achieved? Psychiatr Serv. 2001;52:1469–1478.
    1. Opbroek A., Delgado P.L., Laukes C., McGahuey C., Katsanis J., Moreno F.A. Emotional blunting associated with SSRI-induced sexual dysfunction: Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol. 2002;5:147–151.
    1. Price J., Cole V., Goodwin G.M. Emotional side-effects of selective serotonin reuptake inhibitors: Qualitative study. Br J Psychiatry. 2009;195:211–217.
    1. Zald D.H., Depue R.A. Serotonergic functioning correlates with positive and negaitive affect in psychiatrically healthy males. Personal Individ Differences. 2001;30:71–86.
    1. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004;29:1765–1781.
    1. Nutt D., Demyttenaere K., Janka Z., Aarre T., Bourin M., Canonico P.L. The other face of depression, reduced positive affect: The role of catecholamines in causation and cure. J Psychopharmacol. 2007;21:461–471.
    1. Dekeyne A., Gobert A., Auclair A., Girardon S., Millan M.J. Differential modulation of efficiency in a food-rewarded “differential reinforcement of low-rate” 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors. Psychopharmacology. 2002;162:156–167.
    1. Fitzgerald D.A., Posse S., Moore G.J., Tancer M.E., Nathan P.J., Phan K.L. Neural correlates of internally-generated disgust via autobiographical recall: A functional magnetic resonance imaging investigation. Neurosci Lett. 2004;370:91–96.
    1. McCabe C., Cowen P.J., Harmer C.J. Neural representation of reward in recovered depressed patients. Psychopharmacology. 2009
    1. Spitzer R.L., Williams J.B., Gibbon M., First M.B. Structured clinical interview for the DSM-IV (SCID-I/P) 2004
    1. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571.
    1. Spielberger C.D. Consulting Psychologists Publishing; Palo Alto, CA: 1983. Manual for the State-Trait Anxiety Inventory.
    1. Fawcett J., Clark D.C., Scheftner W.A., Gibbons R.D. Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry. 1983;40:79–84.
    1. Snaith R.P., Hamilton M., Morley S., Humayan A., Hargreaves D., Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167:99–103.
    1. Rolls E.T., McCabe C. Enhanced affective brain representations of chocolate in cravers vs. non-cravers. Eur J Neurosci. 2007;26:1067–1076.
    1. Garner D.M., Olmsted M.P., Bohr Y., Garfinkel P.E. The eating attitudes test: Psychometric features and clinical correlates. Psychol Med. 1982;12:871–878.
    1. O'Doherty J., Rolls E.T., Francis S., Bowtell R., McGlone F. The representation of pleasant and aversive taste in the human brain. J Neurophysiol. 2001;85:1315–1321.
    1. de Araujo I.E.T., Kringelbach M.L., Rolls E.T., Hobden P. The representation of umami taste in the human brain. J Neurophysiol. 2003;90:313–319.
    1. de Araujo I.E.T., Kringelbach M.L., Rolls E.T., McGlone F. Human cortical responses to water in the mouth, and the effects of thirst. J Neurophysiol. 2003;90:1865–1876.
    1. de Araujo I.E.T., Rolls E.T. The representation in the human brain of food texture and oral fat. J Neurosci. 2004;24:3086–3093.
    1. Wilson J.L., Jenkinson M., de Araujo I., Kringelbach M.L., Rolls E.T., Jezzard P. Fast, fully automated global and local magnetic field optimization for fMRI of the human brain. Neuroimage. 2002;17:967–976.
    1. Collins D.L., Neelin P., Peters T.M., Evans A.C. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192–205.
    1. Friston K.J., Glaser D.E., Henson R.N., Kiebel S., Phillips C., Ashburner J. Classical and Bayesian inference in neuroimaging: Applications. Neuroimage. 2002;16:484–512.
    1. Friston K.J., Worsley K.J., Frackowiak R.S.J., Mazziotta J.C., Evans A.C. Assessing the significance of focal activations using their spatial extent. Hum Brain Mapp. 1994;1:214–220.
    1. Worsley K.J., Marrett P., Neelin A.C., Friston K.J., Evans A.C. A unified statistical approach for determining significant signals in images of cerebral activation. Hum Brain Mapp. 1996;4:58. 73.
    1. Glascher J., Gitelman D. Contrast weights in flexible factorial design with multiple groups of subjects. 2008.
    1. McCabe C., Rolls E.T., Bilderbeck A., McGlone F. Cognitive influences on the affective representation of touch and the sight of touch in the human brain. Soc Cogn Affect Neurosci. 2008;3:97–108.
    1. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI datasets. Neuroimage. 2003;19:1233–1239.
    1. Epstein J., Pan H., Kocsis J.H., Yang Y., Butler T., Chusid J. Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. Am J Psychiatry. 2006;163:1784–1790.
    1. Knutson B., Bhanji J.P., Cooney R.E., Atlas L.Y., Gotlib I.H. Neural responses to monetary incentives in major depression. Biol Psychiatry. 2008;63:686–692.
    1. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19:567–596.
    1. Oleshansky M.A., Labbate L.A. Inability to cry during SRI treatment. J Clin Psychiatry. 1996;57:593.
    1. Taylor M.J., Freemantle N., Geddes J.R., Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and meta-analysis. Arch Gen Psychiatry. 2006;63:1217–1223.
    1. Harmer C.J., Shelley N.C., Cowen P.J., Goodwin G.M. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004;161:1256–1263.
    1. Dannon P.N., Iancu I., Lowengrub K., Gonopolsky Y., Musin E., Grunhaus L. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol. 2007;30:326–334.
    1. Halford J.C., Harrold J.A., Boyland E.J., Lawton C.L., Blundell J.E. Serotonergic drugs: Effects on appetite expression and use for the treatment of obesity. Drugs. 2007;67:27–55.
    1. Stice E., Spoor S., Bohon C., Small D.M. Relation between obesity and blunted striatal response to food is moderated by Taq1A A1 allele. Science. 2008;322:449–452.
    1. Arroll B., Elley C.R., Fishman T., Goodyear-Smith F.A., Kenealy T., Blashki G. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev. 2009 CD:007954.
    1. Ipser J.C., Stein D.J., Hawkridge S., Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst. Rev. 2009 CD:005170.
    1. Nelson J.C., Portera L., Leon A.C. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor? Biol Psychiatry. 2005;57:1535–1542.
    1. Trivedi M.H., Hollander E., Nutt D., Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry. 2008;69:246–258.
    1. Papakostas G.I., Nutt D.J., Hallett L.A., Tucker V.L., Krishen A., Fava M. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006;60:1350–1355.
    1. Papakostas G.I., Stahl S.M., Krishen A., Seifert C.A., Tucker V.L., Goodale E.P. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): A pooled analysis of 10 studies. J Clin Psychiatry. 2008;69:1287–1292.
    1. Papakostas G.I., Thase M.E., Fava M., Nelson J.C., Shelton R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder?: A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62:1217–1227.
    1. Zisook S., Rush A.J., Haight B.R., Clines D.C., Rockett C.B. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry. 2006;59:203–210.
    1. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231–1242.
    1. Trivedi M.H., Fava M., Wisniewski S.R., Thase M.E., Quitkin F., Warden D. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–1252.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe